Polaryx Therapeutics (PLYX) Accounts Payables (2024 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Accounts Payables of $850000.0 for Q1 2026, up 80.85% quarter-over-quarter from $470000.0 in Q4 2025.

Polaryx Therapeutics (PLYX) Accounts Payables (2024 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Accounts Payables for 3 consecutive years, with $850000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Accounts Payables changed N/A year-over-year to $850000.0; the TTM figure through Mar 2026 stood at $850000.0 (changed N/A YoY), while the FY2025 annual figure was $470000.0, up 552.78% from the prior year.
Accounts Payables climbed to $850000.0 in Q1 2026 per PLYX's latest filing, from $470000.0 in the prior quarter.
Across five years, Accounts Payables topped out at $850000.0 in Q1 2026 and bottomed at $72000.0 in Q4 2024.
Historically, Accounts Payables has averaged $464000.0 across 3 years, with a median of $470000.0 in 2025.
On a YoY basis, Accounts Payables climbed as much as 552.78% in 2025 and fell as far as 552.78% in 2025.
Polaryx Therapeutics' Accounts Payables stood at $72000.0 in 2024, then surged by 552.78% to $470000.0 in 2025, then soared by 80.85% to $850000.0 in 2026.
Business Quant data shows PLYX's Accounts Payables at $850000.0 in Q1 2026, $470000.0 in Q4 2025, and $72000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Accounts Payables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.52 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	108.02 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	622.65 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	428.93 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	35.57 Mn
10	Polaryx Therapeutics	99.45 Mn	87.91 Mn	-	683,000.00

Download Data